Hologic, Inc. (NASDAQ:HOLX) Stock Position Decreased by Nuveen Asset Management LLC

Nuveen Asset Management LLC reduced its position in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 18.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 502,916 shares of the medical equipment provider's stock after selling 112,516 shares during the period. Nuveen Asset Management LLC owned approximately 0.22% of Hologic worth $36,255,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of HOLX. Venturi Wealth Management LLC grew its stake in Hologic by 156.3% during the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock valued at $31,000 after purchasing an additional 261 shares in the last quarter. EverSource Wealth Advisors LLC raised its holdings in Hologic by 79.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock valued at $42,000 after acquiring an additional 260 shares in the last quarter. Smartleaf Asset Management LLC boosted its stake in Hologic by 36.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock valued at $43,000 after acquiring an additional 159 shares during the last quarter. Smithfield Trust Co increased its position in shares of Hologic by 160.0% in the 4th quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider's stock worth $45,000 after purchasing an additional 400 shares during the last quarter. Finally, Sound Income Strategies LLC bought a new stake in shares of Hologic in the 4th quarter worth about $60,000. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Hologic Price Performance

HOLX stock traded down $0.20 during trading hours on Monday, hitting $54.28. 2,268,541 shares of the stock traded hands, compared to its average volume of 2,144,938. The stock has a 50-day simple moving average of $58.17 and a 200 day simple moving average of $66.43. The company has a market cap of $12.10 billion, a P/E ratio of 17.12, a P/E/G ratio of 2.14 and a beta of 0.54. Hologic, Inc. has a one year low of $51.90 and a one year high of $84.67. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share for the quarter, beating analysts' consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. The company had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. During the same period in the prior year, the company earned $1.03 EPS. Hologic's revenue was down 1.2% on a year-over-year basis. Equities analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Wall Street Zen downgraded Hologic from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. Raymond James restated an "outperform" rating and set a $71.00 price objective (down from $90.00) on shares of Hologic in a research note on Friday, May 2nd. Morgan Stanley decreased their price objective on shares of Hologic from $77.00 to $65.00 and set an "equal weight" rating for the company in a report on Monday, May 5th. Stephens dropped their target price on shares of Hologic from $77.00 to $70.00 and set an "overweight" rating on the stock in a report on Tuesday, May 13th. Finally, Argus lowered shares of Hologic from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. Twelve equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $77.42.

Insider Activity at Hologic

In related news, Director Martin D. Madaus bought 5,445 shares of the firm's stock in a transaction that occurred on Wednesday, May 7th. The shares were acquired at an average cost of $55.24 per share, for a total transaction of $300,781.80. Following the acquisition, the director now directly owns 5,445 shares of the company's stock, valued at $300,781.80. The trade was a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 1.88% of the company's stock.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.